Liposomes: Advancements and innovation in the manufacturing process

Shah, Sanket M.; Dhawan, Vivek; Holm, René; Nagarsenker, Mangal S.; Perrie, Yvonne

doi:10.1016/j.addr.2020.07.002

Cited by 372 publications

(260 citation statements)

References 150 publications

Supporting

Mentioning

227

Contrasting

Order By: Relevance

“…In brief, liposomes, structured by phospholipids and cholesterol, have great drug protection and targeting abilities [ 27 ]. These properties lead to liposomes having reduced toxicity with improved efficacy over free drug in the systemic circulation [ 6 ]. The application of liposomes in dermal delivery is limited due to their lack of penetrating ability in the stratum corneum.…”

Section: Lipid-based Nanoparticlesmentioning

confidence: 99%

“…Lipid nanoparticles are multicomponent lipid systems typically containing a phospholipid, an ionizable lipid, cholesterol, and a PEGylated lipid [ 5 ]. The traditional type of lipid nanoparticles is liposomes which was first described in 1961 by the British haematologist, Alec D Bangham [ 6 ]. Liposomes were observed under the electron microscope when adding negative stain to dry phospholipids that assembled into spherical shape through a lipid bilayer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

COVID-19 vaccines have been developed with unprecedented speed which would not have been possible without decades of fundamental research on delivery nanotechnology. Lipid-based nanoparticles have played a pivotal role in the successes of COVID-19 vaccines and many other nanomedicines, such as Doxil® and Onpattro®, and have therefore been considered as the frontrunner in nanoscale drug delivery systems. In this review, we aim to highlight the progress in the development of these lipid nanoparticles for various applications, ranging from cancer nanomedicines to COVID-19 vaccines. The lipid-based nanoparticles discussed in this review are liposomes, niosomes, transfersomes, solid lipid nanoparticles, and nanostructured lipid carriers. We particularly focus on the innovations that have obtained regulatory approval or that are in clinical trials. We also discuss the physicochemical properties required for specific applications, highlight the differences in requirements for the delivery of different cargos, and introduce current challenges that need further development. This review serves as a useful guideline for designing new lipid nanoparticles for both preventative and therapeutic vaccines including immunotherapies.

show abstract

Section: Lipid-based Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Liposomes are widely-studied nano-sized lipid vesicles that could be beneficial in the delivery of drugs via the dermal or transdermal routes. Liposomes, as drug carriers, offer many advantages that are reported elsewhere [ 134 , 135 , 136 ].…”

Section: Vesicular Formulationsmentioning

confidence: 99%

Delivery of Insulin via Skin Route for the Management of Diabetes Mellitus: Approaches for Breaching the Obstacles

et al. 2021

View full text Add to dashboard Cite

Insulin is used for the treatment of diabetes mellitus, which is characterized by hyperglycemia. Subcutaneous injections are the standard mode of delivery for insulin therapy; however, this procedure is very often invasive, which hinders patient compliance, particularly for individuals requiring insulin doses four times a day. Furthermore, cases have been reported of sudden hypoglycemia occurrences following multidose insulin injections. Such an invasive and intensive approach motivates the quest for alternative, more user-friendly insulin administration approaches. For example, transdermal delivery has numerous advantages, such as prolonged drug release, low variability in the drug plasma level, and improved patient compliance. In this paper, the authors summarize different approaches used in transdermal insulin delivery, including microneedles, chemical permeation enhancers, sonophoresis, patches, electroporation, iontophoresis, vesicular formulations, microemulsions, nanoparticles, and microdermabrasion. Transdermal systems for insulin delivery are still being widely researched. The conclusions presented in this paper are extracted from the literature, notably, that the transdermal route could effectively and reliably deliver insulin into the circulatory system. Consistent progress in this area will ensure that some of the aforementioned transdermal insulin delivery systems will be introduced in clinical practice and commercially available in the near future.

show abstract

“…Among various types of clinically used formulations, lipid‐based carriers hold a big share for their incomparable advantages, such as excellent biocompatibility, [ 24,25 ] negligible optical interference, [ 26 ] diverse modifiable groups, [ 27 ] high water‐solubility, and stability. [ 16,28 ] Besides, the hydrophobic tail and hydrophilic head sections endow lipid amphiphilic property, which is diversely used as a delivery platform for different properties of drugs.…”

Section: Introductionmentioning

confidence: 99%

AIEgen–lipid structures: Assembly and biological applications

Cao

Yang

2020

Aggregate

View full text Add to dashboard Cite

Aggregation‐induced emission (AIE) molecules possess notable advantages outperforming traditional aggregation caused quenching (ACQ) materials on various aspects. They are rapidly developed these years. More and more AIE luminogens (AIEgens) are designed to possess multifunctions such as the abilities of near‐infrared two‐photon absorption and reactive oxygen species (ROS) generation, which could be used for deep tissue imaging and photodynamic therapy. The AIEgens exhibit great potential in biological application field. However, despite the photophysics stability and ROS generation ability in aggregated states are favorable conditions, their applications in biological field are retarded by uncontrolled size, single imaging mode, low targeting efficiency, and also poor biocompatibility and dispersibility in physiological environment. The combination of AIEgen and lipid is a straightforward, promising, and intensively used way to solve the above problems. Due to the special amphipathic property of lipid, which results from a hydrophilic head and hydrophobic tail structure, there are various possibilities of combination modes between lipid and AIEgen. Even a little procedure or condition change during the synthesis process will impact the structure of obtained product, which can further influence its application. Herein, we summarize the synthesis methods of different AIEgen–lipid compounds with diverse structures and properties, as well as their biological applications in this contribution, which has not been presented before, being aimed at serving as a synthesis and application reference for these promising AIEgen–lipid compounds applied in biological region.

show abstract

Liposomes: Advancements and innovation in the manufacturing process

Cited by 372 publications

References 150 publications

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Delivery of Insulin via Skin Route for the Management of Diabetes Mellitus: Approaches for Breaching the Obstacles

AIEgen–lipid structures: Assembly and biological applications

Contact Info

Product

Resources

About